This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder
Sponsor: Astellas Pharma Europe B.V.
Listed as NCT01972841, this PHASE3 trial focuses on Overactive Bladder and Urgency Incontinence and remains completed. Sponsored by Astellas Pharma Europe B.V., it has been updated 17 times since 2013, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
17 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE3
-
Nov 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Nov 2024 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
▶ Show 12 earlier versions
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE3
-
Sep 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Dec 2018 — Sep 2020 [monthly]
Completed PHASE3
-
Aug 2018 — Dec 2018 [monthly]
Completed PHASE3
-
Jul 2018 — Aug 2018 [monthly]
Completed PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Completed PHASE3
-
Oct 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jun 2017 — Oct 2017 [monthly]
Completed PHASE3
-
May 2017 — Jun 2017 [monthly]
Completed PHASE3
-
Feb 2017 — May 2017 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Nov 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Astellas Pharma Europe B.V.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aalborg, Denmark , Aarhus, Denmark , Albany, United States , Albuquerque, United States , Alpharetta, United States , Amsterdam, Netherlands , Anaheim, United States , Ancona, Italy , Ankara, Turkey (Türkiye) , Athens, Greece and 332 more locations